Objective: Identify risk factors for readmission due to a bacterial tracheostomy-associated respiratory tract infection (bTARTI) within 12 months of discharge after tracheotomy. Readmission for a bTARTI (eg, pneumonia, tracheitis) treated with antibiotics, as ascertained by manual chart review, was the outcome variable. We used multivariate logistic regression to identify the independent association between risk factors and hospital readmission for bTARTI within 12 months.
| INTRODUCTION
Hospitalizations in pediatric patients with pre-existing tracheostomy amounted to $1.4 billion in hospital charges in 2012. 1 Of these hospitalizations, bacterial pneumonia is the most common ambulatory care sensitive condition (conditions for which appropriate ambulatory care prevents or reduces admission to the hospital) 2 requiring hospitalization. 3 Previous research has shown that the wide diagnostic and therapeutic variations of pediatric patients hospitalized with bacterial tracheostomy-associated respiratory tract infections (bTARTIs) are not associated with length of stay (LOS) or readmission. 4 Because children with tracheostomy account for high utilization of health care resources, 3, [5] [6] [7] identification of high-risk subpopulations, and modifiable factors may assist in development of evidence-based best practices for the prevention and treatment of these infections, and decrease hospital admissions and healthcare expenditures.
Abbreviations: AOR, adjusted odds ratio; bTARTI, bacterial tracheostomyassociated respiratory tract infection; CF, cystic fibrosis; CHLA, Childrens Hospital Los Angeles; CI, confidence interval; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; IQR, interquartile range; LOS, length of stay; PHIS, Pediatric Health Information System; UOR, unadjusted odds ratio.
One reason for frequent pneumonia hospitalizations is that up to 90% of pediatric patients with tracheostomy have respiratory cultures positive for Pseudomonas aeruginosa (P. aeruginosa), a multidrug resistant bacterium with limited oral treatment options, at some point post-tracheotomy. 8 Indeed, over 70% of pediatric patients hospitalized bTARTIs receive empiric antibiotics that target P. aeruginosa). 4 While previous literature in patients with cystic fibrosis (CF) demonstrated associations between P. aeruginosa acquisition and both increased CF exacerbation rates, 9 and declining pulmonary status and greater mortality, 10-14 the relationship between P. aeruginosa and outcomes in pediatric patients with tracheostomy remains unclear.
Because of the large number of children who undergo tracheotomy at our center each year, we saw an opportunity to further investigate risk factors for a bTARTI requiring readmission after tracheotomy surgery in pediatric patients, with a focus on acquisition of P. aeruginosa. The objective of the current study was to identify risk factors for readmission due to a bTARTI within 12 months of hospitalization for tracheotomy. 
| Primary outcome variable
Through chart review, we identified the outcome variable as the first hospitalization for a bTARTI, defined as a discharge diagnosis of a bacterial respiratory tract infection (eg, pneumonia, tracheitis) on review of the discharge summary, treated with a complete course of antibiotic therapy (as defined by the primary team) or discharge home to complete antibiotic therapy. One medical student and one research staff member trained in medical chart abstraction identified the outcome variables; discrepancies were resolved through a secondary review by the principal investigator (CR).
| Statistical methodology
Descriptive statistics and bivariate analyses were first used to assess the association between predictor variables and covariates with readmission for bTARTI. Bivariate logistic regressions for binary outcomes and linear regressions for continuous outcomes were reported through unadjusted odds ratios (UOR) with 95% confidence intervals (CI). Predictor variables that maintained a P < 0.15 significance level, or had demographic or medical justification for inclusion in the multivariate analysis (male gender, public insurance, age at admission) were used. Adjusted odds ratios (AOR) with 95%CI were UOR for factors associated with hospitalization for bTARTI are presented in Table 1 . In bivariate analysis, risk factors statistically The multivariable logistic regression model is presented in Table 2 . For the 103 patients readmitted with a bTARTI, we found an association between initial timing of first P. aeruginosapositive respiratory culture and P. aeruginosa identification on hospital readmission for first bTARTI. Patients with a P. aeruginosapositive respiratory culture prior to post-tracheotomy discharge were more likely to have a P. aeruginosa-positive respiratory culture on bTARTI readmission, when compared to patients without a P. aeruginosa-positive respiratory culture (64.1% vs 35.9%; P = 0.003).
However, there was no difference in subsequent P. aeruginosa-positive bTARTI readmission respiratory culture for those patients with P. aeruginosa prior to tracheotomy, when compared to those who acquired P. aeruginosa between tracheotomy and discharge (59.1% vs 70.6%; P = 0.46).
| DISCUSSION
In this single center retrospective study of pediatric patients undergoing tracheotomy, nearly half of patients undergoing tracheotomy are readmitted within 12 months for a bTARTI. Hispanic ethnicity and hospital-acquired P. aeruginosa after tracheotomy and before discharge are independently associated with increased odds, while discharge on pro-motility agents was associated with decreased odds of bTARTI readmission after controlling for potential confounders.
Finally, acquisition of respiratory tract P. aeruginosa prior to posttracheotomy discharge was associated with subsequent readmission for a P. aeruginosa bTARTI.
Our finding of poorer outcomes for those who acquire P. aeruginosa after tracheotomy but prior to initial post-tracheotomy discharge is consistent with poorer outcomes after P. aeruginosa acquisition in other respiratory diseases. As noted previously, up to 90% of pediatric patients with tracheostomy demonstrate P. aeruginosa in a respiratory culture at some time. 8 Our study demonstrates that P. aeruginosa acquisition while hospitalized after tracheotomy is associated with poorer healthcare outcomes, and may be considered a healthcareacquired infection. In pediatric CF, another disease of impaired airway clearance, eradication of P. aeruginosa is feasible after antibiotic administration via inhalation antibiotics, oral/parenteral antibiotics, or a combination of both delivery methods, [22] [23] [24] [25] and leads to reductions in chronic P. aeruginosa infection. 26 Further, failure to eradicate P. aeruginosa after initial acquisition is associated with greater exacerbation risk. 27 Given that P. aeruginosa acquisition may be potentially modifiable, we believe that acquisition during the posttracheotomy recovery period may warrant aggressive eradication measures to prevent readmission. ) and in those undergoing surgical procedures (eg, congenital heart surgery repair). 31 The poorer outcomes may be due to biological differences, socioeconomic differences (eg, access to care, language difficulties), decreased use of home health services and post-acute facilities or a combination.
Pro-motility agents may decrease both frank aspiration and Despite these limitations, this study demonstrates that among pediatric patients who undergoing tracheotomy, those of Hispanic ethnicity and those who acquire P. aeruginosa are at increased odds of 
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